These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 16464192)

  • 1. Data collection methods in prospective economic evaluations: how accurate are the results?
    Evans CJ; Crawford B
    Value Health; 2000; 3(4):277-86. PubMed ID: 16464192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluations relating to diabetes: a descriptive review and their compliance with guidance.
    Oliver A; Pritchard C
    Value Health; 2000; 3 Suppl 1():7-14. PubMed ID: 16464205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In search of the evidentiary foundation of published Canadian economic evaluations (2001-06).
    Tarride JE; Lim ME; Bowen JM; McCarron CE; Blackhouse G; Hopkins R; O'Reilly D; Xie F; Goeree R
    Int J Technol Assess Health Care; 2009 Apr; 25(2):214-21. PubMed ID: 19331712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative decision analysis modeling in the economic evaluation of tumor necrosis factor inhibitors for rheumatoid arthritis.
    Kamal KM; Miller LA; Kavookjian J; Madhavan S
    Semin Arthritis Rheum; 2006 Aug; 36(1):50-60. PubMed ID: 16887468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of self-assessment on the identification of learner needs, learner activity, and impact on clinical practice: BEME Guide no. 10.
    Colthart I; Bagnall G; Evans A; Allbutt H; Haig A; Illing J; McKinstry B
    Med Teach; 2008; 30(2):124-45. PubMed ID: 18464136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of transparency of cost estimates in economic evaluations of patient safety programmes.
    Fukuda H; Imanaka Y
    J Eval Clin Pract; 2009 Jun; 15(3):451-9. PubMed ID: 19366392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of resource utilization estimates from piggyback studies in rheumatoid arthritis.
    Evans C; Crawford B; Doyle J
    Expert Rev Pharmacoecon Outcomes Res; 2003 Dec; 3(6):685-9. PubMed ID: 19807346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    O'Sullivan AK; Thompson D; Drummond MF
    Value Health; 2005; 8(1):67-79. PubMed ID: 15841896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Project evaluation guidelines.
    Keyonzo NA
    Afya; 1989; 23(1):25-33. PubMed ID: 12319637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological issues affecting the value of patient-reported outcomes data.
    Hufford MR; Shiffman S
    Expert Rev Pharmacoecon Outcomes Res; 2002 Apr; 2(2):119-28. PubMed ID: 19807324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2014 Rossi Award lecture:* beyond internal validity.
    Orr LL
    Eval Rev; 2015 Apr; 39(2):167-78. PubMed ID: 25805301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target validity: Bringing treatment of external validity in line with internal validity.
    Lesko CR; Ackerman B; Webster-Clark M; Edwards JK
    Curr Epidemiol Rep; 2020 Sep; 7(3):117-124. PubMed ID: 33585162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ON THE EXTENT OF THE VALIDITY OF THE "RULE OF SHIFT".
    Levene PA; Rothen A; Meyer GM
    Science; 1934 Jul; 80(2065):101-2. PubMed ID: 17743174
    [No Abstract]   [Full Text] [Related]  

  • 16. [21] Data collection strategy.
    Dauter Z
    Methods Enzymol; 1997; 276():326-344. PubMed ID: 27799104
    [No Abstract]   [Full Text] [Related]  

  • 17. Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework.
    Janssen LMM; Drost RMWA; Paulus ATG; Garfield K; Hollingworth W; Noble S; Thorn JC; Pokhilenko I; Evers SMAA
    Pharmacoeconomics; 2021 Sep; 39(9):983-993. PubMed ID: 34169466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and cost drivers associated with setting-up a prime vendor system to complement the national medicines supply chain in Tanzania.
    Kuwawenaruwa A; Wyss K; Wiedenmayer K; Tediosi F
    BMJ Glob Health; 2020 Sep; 5(9):. PubMed ID: 32928801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The short-term effects of the implementation of the "Treat All" guidelines on ART service delivery costs in Namibia.
    Schutte C; Forsythe S; Mdala JF; Zieman B; Linder R; Vu L
    PLoS One; 2020; 15(1):e0228135. PubMed ID: 31986182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and costs of services and unpaid care for people with mild-to-moderate dementia: Baseline results from the IDEAL cohort study.
    Henderson C; Knapp M; Nelis SM; Quinn C; Martyr A; Wu YT; Jones IR; Victor CR; Pickett JA; Hindle JV; Jones RW; Kopelman MD; Matthews FE; Morris RG; Rusted JM; Thom JM; Clare L;
    Alzheimers Dement (N Y); 2019; 5():685-696. PubMed ID: 31720369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.